featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

A “no deal” Brexit scenario may start a domino effect for a “collapse” in the UK pharmaceutical industry

Research published by several investigators in UK universities, including York University, King’s College, London and Queen Mary University, London, states that “the uncertainty of a “no-deal” outcome has already started a domino effect that could lead to the UK pharmaceutical industry’s collapse” (European Medical Writers Association, December 2018). In the recent article, several three potential […]

Read full story
Featured

***EURETINA launch the Retinal Medicine Clinical Research Funding Call***

The 2019 EURETINA Clinical Research Awards have initiated a new funding research Call to support and encourage independent clinical research in the field of retinal medicine. Clinical research, as proposed by clinician or non-clinician researchers, may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history […]

Read full story
Research

High-throughput clinical research testing use a large inherited retinal dystrophy

A research report of the first clinically validated high-throughput next gene sequencing (NGS) technology indicates that sensitivity and specificity had 100% used with the caveat of unclear zygosity calling for one large duplication case. The researchers demonstrated that a reliable NGS-based diagnosis showed by the retinitis pigmentosa GTPase regulator (RPGR) ORF15 mutations. The researchers previously […]

Read full story
Introduction

February 16th, 2019: “EURETINA-Brief”© Issue No. 187

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the February 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story
Featured

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Latest News

Book Review